Stereotactic Radiosurgery · Cranial
Less-Common Cranial Targets
Glomus tumors, chordoma and chondrosarcoma, hemangioblastoma, uveal melanoma, and pediatric considerations
Beyond the high-volume indications, radiosurgery has an established or emerging role in a scattered set of cranial and skull-base targets — usually where the tumor is benign or indolent but surgically morbid, or where it is radioresistant and needs dose escalation. This page surveys those targets, the dose principles, and where particle therapy or another modality is preferred.
Orientation
The common thread among these targets is that open surgery is either high-morbidity or incomplete, making a focal, conformal dose attractive — but the radiobiology varies enormously. Glomus tumors and hemangioblastomas are benign and respond to modest control doses; chordoma and chondrosarcoma are radioresistant and demand high doses often best delivered with protons; uveal melanoma sits at the border with ocular oncology. Recognizing which bucket a tumor falls into — benign-control, radioresistant-dose-escalation, or modality-specific — is the organizing skill.
Glomus Tumors (Paraganglioma)
1.The vascular skull-base tumor where SRS shines
Glomus jugulare and other head-and-neck paragangliomas are highly vascular, benign, slow-growing tumors of the jugular foramen and temporal bone whose resection risks lower-cranial-nerve injury and significant bleeding. Radiosurgery achieves local control on the order of 90%+ with low rates of new cranial-nerve deficit, at modest marginal doses (commonly ~13–16 Gy), as primary treatment or for residual/recurrent disease. The goal, as with other benign tumors, is durable growth arrest with function preservation, and SRS has become a leading option precisely because it avoids the morbidity of resecting a vascular tumor wrapped around the lower cranial nerves.
Chordoma and Chondrosarcoma
2.Radioresistant tumors that need high dose
Clival/skull-base chordomas and chondrosarcomas are locally aggressive and relatively radioresistant, requiring high total doses for control. Management is maximal safe resection followed by high-dose radiotherapy, and because the required dose abuts the brainstem and optic apparatus, proton/particle therapy is frequently preferred for its dose-distribution advantage in dose escalation. Radiosurgery has a role as a boost or for small residual/recurrent disease at a safe distance from critical structures. Chondrosarcoma generally carries a better prognosis than chordoma. The key teaching point is that a tight single-fraction margin alone is usually inadequate for these radioresistant tumors — they are a dose-escalation problem.
Hemangioblastoma
3.Benign, often multiple, sometimes VHL
Hemangioblastomas — sporadic or part of von Hippel-Lindau disease — are benign, highly vascular tumors of the cerebellum, brainstem, and spinal cord, frequently multiple in VHL. Radiosurgery offers control of the solid tumor nodule (~85–90%+) and is especially useful for small, multiple, or surgically inaccessible (brainstem) lesions, sparing the patient repeated craniotomies. Its limitation is the cystic component: SRS treats the mural nodule but does not address an associated symptomatic cyst, which may still require drainage or resection.
Uveal Melanoma and Pediatric Considerations
4.Ocular tumors and children
Uveal (choroidal) melanoma is managed within ocular oncology, where proton beam therapy and episcleral plaque brachytherapy are the established globe-conserving treatments; Gamma Knife/LINAC radiosurgery is an alternative at some centers for eye-preserving treatment of selected tumors. In pediatric patients, the long latency for late radiation effects — secondary malignancy, neurocognitive and endocrine sequelae — weighs heavily, so integral-dose-sparing proton therapy and fractionation are often favored over single-fraction photon SRS, and indications are individualized with particular caution. Other rare cranial targets (e.g., selected ependymomas, hemangiopericytoma/solitary fibrous tumor, recurrent gliomas) are handled case by case within multidisciplinary review.
| Target | Radiobiology / role | Note |
|---|---|---|
| Glomus / paraganglioma | Benign; SRS ~13–16 Gy, control ~90%+ | Avoids morbid resection of vascular jugular-foramen tumor |
| Chordoma | Radioresistant; resection + high-dose RT (often protons) | SRS as boost/residual; tight single-fraction margin inadequate alone |
| Chondrosarcoma | Radioresistant; as above | Better prognosis than chordoma |
| Hemangioblastoma | Benign nodule; SRS control ~85–90%+ | Sporadic or VHL; cyst not addressed by SRS |
| Uveal melanoma | Proton/plaque standard; SRS an alternative | Within ocular oncology |
| Pediatric / rare | Favor protons/fractionation; individualized | Late-effect and secondary-malignancy concern |
Key points
- Sort the target: benign-control (glomus, hemangioblastoma), radioresistant-dose-escalation (chordoma, chondrosarcoma), or modality-specific (uveal melanoma, pediatric).
- Glomus/paraganglioma: SRS ~13–16 Gy gives ~90%+ control with cranial-nerve preservation — avoids morbid resection of a vascular skull-base tumor.
- Chordoma/chondrosarcoma are radioresistant: resection + high-dose RT (often protons); SRS is a boost/residual tool, not a standalone tight-margin treatment.
- Hemangioblastoma (sporadic/VHL): SRS controls the solid nodule (~85–90%+) but not an associated symptomatic cyst.
- Uveal melanoma is proton/plaque territory with SRS as an alternative; in children, favor proton/fractionation and individualize given late-effect risk.
References
- Ibrahim R, Ammori MB, Yianni J, Grainger A, Rowe J, Radatz M. Gamma Knife radiosurgery for glomus jugulare tumors: a single-center series of 75 cases. J Neurosurg. 2017;126(5):1488–1497. PubMed
- Ong V, Bourcier AJ, Florence TJ, et al. Stereotactic radiosurgery for glomus jugulare tumors: systematic review and meta-analysis. World Neurosurg. 2022;162:e49–e57. PubMed
- Stacchiotti S, Sommer J; Chordoma Global Consensus Group. Building a global consensus approach to chordoma: a position paper from the medical and patient community. Lancet Oncol. 2015;16(2):e71–e83. PubMed
- Kano H, Shuto T, Iwai Y, et al. Stereotactic radiosurgery for intracranial hemangioblastomas: a retrospective international outcome study. J Neurosurg. 2015;122(6):1469–1478. PubMed
Educational survey for neurosurgery and radiation-oncology trainees; doses and control rates are representative, not a treatment directive, and these less-common indications are managed within multidisciplinary review. Rare cranial target references verified against PubMed during review.